The significant year-over-year revenue decline and increased losses may pressure shares despite the company's strong cash position and ongoing clinical advancements. Investors should monitor upcoming clinical data readouts and potential partnership renewals.
Price Chart
Executive Summary
Nurix Therapeutics reported Q1 2026 financial results with revenue of $6.3 million, down from $18.5 million in the prior year quarter, and a net loss per share of $0.79. The company continues to advance its bexobrutideg clinical program while maintaining a $540.7 million cash position.
Key Financial Metrics
Key Facts
- Revenue for Q1 2026 was $6.3 million, down from $18.5 million in Q1 2025
- Net loss was $87.2 million, or $0.79 per share, compared to $56.4 million, or $0.67 per share, in the prior year quarter
- Cash, cash equivalents and marketable securities were $540.7 million as of February 28, 2026
- Research and development expenses increased to $84.1 million from $69.7 million in the prior year quarter
- The decrease in revenue was primarily due to the conclusion of the initial research term for certain drug targets with Sanofi
Financial Impact
Revenue decreased by $12.2 million year-over-year, with increased R&D spending contributing to larger net loss
Risk Factors
- Continued revenue decline as collaboration agreements conclude
- Increasing R&D expenses without near-term commercial products
- Dependence on successful clinical trial outcomes for future value creation
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001549595-26-000024 |
| Document: nrix-20260408.htm | 0001549595-26-000024 |
| Document: 0001549595-26-000024-index-headers.html | 0001549595-26-000024 |
| Document: 0001549595-26-000024-index.html | 0001549595-26-000024 |
| Document: 0001549595-26-000024.txt | 0001549595-26-000024 |
| 8-K Data (Synthetic) | 0001549595-26-000024 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 2, 2026 29d ago | Insider Cluster | $25.32 $25.10 | ▼ −0.87% | ▲ +0.28% | $22.89 (−9.60%) |
Aug 5, 2026 8w ago | Insider Cluster | $25.22 $27.19 | ▲ +7.81% | ▲ +6.60% | $22.89 (−9.24%) |
Aug 5, 2026 8w ago | Insider Cluster | $25.12 $26.63 | ▲ +6.01% | ▲ +5.66% | $22.89 (−8.88%) |
Aug 5, 2026 8w ago | Insider Cluster | $25.12 $26.63 | ▲ +6.01% | ▲ +5.66% | $22.89 (−8.88%) |
Aug 3, 2026 8w ago | Insider Cluster | $24.69 $25.96 | ▲ +5.14% | ▲ +5.24% | $22.89 (−7.29%) |
Jul 30, 2026 9w ago | Insider Cluster | $23.21 $25.53 | ▲ +10.00% | ▲ +6.48% | $22.89 (−1.38%) |
Jul 9, 2026 12w ago | Press Release | $23.06 $23.07 | ▲ +0.04% | ▲ +0.60% | $22.89 (−0.74%) |
Jul 2, 2026 13w ago | Insider Cluster | $23.97 $24.69 | ▲ +3.00% | ▲ +2.07% | $22.89 (−4.51%) |
Jun 11, 2026 16w ago | Institutional Cluster | $16.98 $17.12 | ▲ +0.82% | ▲ +0.39% | $22.89 (+34.81%) |
Jun 8, 2026 16w ago | 8-K | $15.64 $17.04 | ▲ +8.95% | ▲ +6.84% | $22.89 (+46.36%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access